Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 14, 2010; 16(38): 4823-4831
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823
Clinico-pathological feature | Frequency |
Age (yr), median (range) | 64 (26-82) |
Gender | |
Male | 26 (60.5) |
Female | 17 (39.5) |
Response | |
Progressive disease | 19 (44.2) |
Partial response | 13 (30.2) |
Stable disease | 11 (25.6) |
EGFR | |
No Amplification/gene copy number gain | 4 (10.5) |
Amplification/gene copy number gain | 34 (89.5) |
K-RAS | |
Wild-type | 32 (74.4) |
Mutation | 11 (25.6) |
B-RAF | |
Wild-type | 38 (88.4) |
Mutation | 5 (11.6) |
PIK3CA | |
Wild-type | 41 (95.4) |
Mutation | 2 (4.7) |
PTEN | |
Negative | 12 (27.9) |
Positive | 31 (72.1) |
Overall survival time (mo), median (range) | 37.3 (3.6-180) |
Progression-free survival (mo), median (range) | 16.0 (1-171) |
Number of tumor buds, median (range) | 9.0 (1-44) |
Tumor budding | |
High | 11 (25.6) |
Low | 32 (74.4) |
- Citation: Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients. World J Gastroenterol 2010; 16(38): 4823-4831
- URL: https://www.wjgnet.com/1007-9327/full/v16/i38/4823.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i38.4823